Skip Navigation


Annals of Oncology Advance Access originally published online on July 11, 2008
Annals of Oncology 2008 19(9):1656-1657; doi:10.1093/annonc/mdn414
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/9/1656    most recent
mdn414v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Horacek, J. M.
Right arrow Articles by Jebavy, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horacek, J. M.
Right arrow Articles by Jebavy, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity

The first 10% of the full text of this article appears below.

Chemotherapy (CT)-induced cardiotoxicity remains a topical problem in cancer survivors. Anthracyclines represent the greatest risk for development of cardiotoxicity [1]. Various methods including cardiac biomarkers have been recommended for monitoring of cardiotoxicity in oncology. The clinical studies using cardiac troponins for evaluation of anthracycline-induced cardiotoxicity brought inconsistent . . . [Full Text of this Article]

funding

J. M. Horacek1,4,*, M. Tichy2,4, R. Pudil3 and L. Jebavy1,4

1 Second Department of Medicine–Clinical Hematology, Hradec Kralove, Czech Republic
2 Institute of Clinical Biochemistry and Diagnostics, Hradec Kralove, Czech Republic
3 First Department of Medicine, University Hospital and Charles University, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic
4 Department of Internal Medicine, University of Defence, Faculty of Military Health Sciences in Hradec Kralove, Czech Republic

* (E-mail: jan.hor@post.cz)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?